Summary of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings on Apr 16, 2018

April 16, 2018 - By Kyle Williams

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

Total analysts of 3 have positions in Collegium Pharmaceutical (NASDAQ:COLL) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 18, 2017 according to StockzIntelligence Inc Collegium Pharmaceutical has 8 analyst reports. The company rating was maintained by Piper Jaffray on Monday, February 12. On Thursday, December 7 the firm has “Buy” rating by Piper Jaffray given. On Wednesday, October 18 Jefferies maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating. Jefferies has “Buy” rating and $15.0 target. On Monday, November 6 Janney Capital maintained the shares of COLL in report with “Buy” rating. On Wednesday, November 29 the rating was maintained by Piper Jaffray with “Buy”. On Tuesday, January 23 the stock has “Buy” rating by Piper Jaffray. On Sunday, February 11 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given by Jefferies. On Thursday, December 14 the rating was maintained by Piper Jaffray with “Buy”. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain
06/11/2017 Broker: Janney Capital Rating: Buy New Target: $21.0 Maintain
18/10/2017 Broker: Jefferies Rating: Buy New Target: $15.0 Maintain

On during the last trading session the stock decreased $0.83 or 3.57%, reaching $22.45.Collegium Pharmaceutical, Inc. has volume of 81,209 shares. Since April 16, 2017 COLL has risen 133.98% and is uptrending. COLL outperformed by 122.43% the S&P 500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is valued at $741.47 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Currently it has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.